About
The Amyloidosis Forum
Formed in 2019, The Amyloidosis Forum has been developed through a public-private partnership between the Amyloidosis Research Consortium (ARC) and the US Food and Drug Administration (FDA). The overarching goal of the Forum is to optimize innovation and accelerate the advancement of new therapeutics by addressing scientific gaps and needs through the conduct of mutually beneficial scientific activities in the pre-competitive domain.
PPPs and Precompetitive Research
A public–private partnership (PPP) is a cooperative arrangement between two or more public and private sectors, typically of a long-term nature. In 2019, a PPP was formed between the nonprofit Amyloidosis Research Consortium (ARC) and the US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). The goal of this PPP is to identify and bridge the scientific gaps that are acting as barriers to drug discovery and development for the treatment of AL amyloidosis. The PPP seeks to leverage expertise and resources of all stakeholders (academia, industry, patients, and regulatory agencies) for the conduct of mutually beneficial scientific activities in the precompetitive domain to support bringing new, safe and efficacious therapies to patients with AL and ATTR amyloidosis.
Steering Committee
Angela Dispenzieri, MD
Consultant, Division of Hematology; Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine and Pathology; Hematology Research Chair, Mayo Clinic College of Medicine
Isabelle Lousada
Founder and CEO, Amyloidosis Research Consortium
James Signorovitch, PhD
Managing Principal, Health Economics and Outcomes Research, Epidemiology and Biostatistics, Analysis Group, Inc.
Kristen Hsu
Executive Director of Research, Amyloidosis Research Consortium
Mathew S. Maurer, MD
Cardiologist and Medical Director, The HCM Center at New York-Presbyterian Hospital/Columbia University Medical Center
Mona Fiuzat, Pharm D
Senior Scientific Advisor, FDA; Associate Prof. of Medicine, Duke
Preston Dunnmon, MD, MBA, FACP, FACC
Vice President, Data Science, Cardiovascular/Metabolism & Pulmonary Hypertension, Janssen Research and Development (Retired)
Sarah Cairns-Smith, PhD, MBA
Chairman, ARC; Senior Partner and Managing Director, Boston Consulting Group
Sharmila Dorbala, MD, MPH
Director of Nuclear Cardiology, Brigham and Women’s Hospital
Vaishali Sanchorawala, MD
Professor of Medicine. Director, Amyloidosis Center, Boston University School of Medicine and Boston Medical Center
The Amyloidosis Research Consortium
The Amyloidosis Research Consortium (ARC) is a nonprofit organization dedicated to driving advances in the awareness, science, and treatment of amyloid diseases. ARC’s mission is to improve and extend the lives of those with amyloidosis. ARC is committed to collaborative efforts that accelerate the pace of discovery, expand patient access to the most effective care, and improve short- and long-term outcomes. Working with partners in industry, government, and academia, ARC seeks to spark innovation and to bring promising treatments from labs to clinics. ARC’s outreach and education inform and empower patients, families, caregivers, physicians, and researchers.
Visit the ARC WebsiteThank You to Our Supporters
